Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22,060 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 Trial.
Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, Lin D, Chen Y, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Yin Z, Xuan L, Lin R, Jiang X, Yu G, Liu Q. Jin H, et al. Among authors: sun z. J Hematol Oncol. 2023 Apr 29;16(1):42. doi: 10.1186/s13045-023-01437-1. J Hematol Oncol. 2023. PMID: 37120593 Free PMC article. Clinical Trial.
Idarubicin plus BuCy versus BuCy conditioning regimens for intermediate-risk acute myeloid leukemia in first complete remission undergoing auto-HSCT: An open-label, multicenter, randomized phase 3 trial.
Liu H, Huang F, Zhang Y, Wu M, Xu N, Fan Z, Sun Z, Li X, Lin D, Xiong Y, Liu X, Lin R, Shi P, Xu J, Wang Z, Li X, Sun J, Liu Q, Xuan L. Liu H, et al. Among authors: sun z, sun j. Am J Hematol. 2023 Mar;98(3):408-412. doi: 10.1002/ajh.26800. Epub 2023 Jan 1. Am J Hematol. 2023. PMID: 36588387 Free article. Clinical Trial.
Hypomethylating agents plus modified priming regimens compared with venetoclax-based regimens based on molecular characteristics for newly diagnosed patients with acute myeloid leukemia: a multi-center cohort study.
Weng G, Huang J, He X, Xue T, Yang L, Zhang Y, Yu G, Sun Z, Lin D, Deng L, Liang X, Xiao J, Zhang H, Guo Z, Jin H, Liu Q, Du X. Weng G, et al. Among authors: sun z. Ann Hematol. 2023 Dec;102(12):3369-3381. doi: 10.1007/s00277-023-05452-7. Epub 2023 Sep 18. Ann Hematol. 2023. PMID: 37723307
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 study.
Yu S, Zhang Y, Yu G, Wang Y, Shao R, Du X, Xu N, Lin D, Zhao W, Zhang X, Xiao J, Sun Z, Deng L, Liang X, Zhang H, Guo Z, Dai M, Shi P, Huang F, Fan Z, Liu Q, Lin R, Jiang X, Xuan L, Liu Q, Jin H. Yu S, et al. Among authors: sun z. J Intern Med. 2024 Feb;295(2):216-228. doi: 10.1111/joim.13738. Epub 2023 Oct 29. J Intern Med. 2024. PMID: 37899297 Clinical Trial.
Chinese expert consensus on the management of patients with hematologic malignancies infected with SARS-CoV-2.
Wang J, Shao L, Liang J, Wu Q, Zhu B, Deng Q, Liu Z, Liu L, Wang D, Yu Z, Tan X, Wang F, Meng J, Xu X, Xia Z, Li Z, Wang H, Wang L, Wu W, Xie Q, Huang X, Sun Z, Zhang Y, Zhou H, Zhou H, Yang W, Ren H, Liu Z, Qiao M, Tang F, Qi X, Wu H, Deng L, Gao L, Zhang H, Chen P, Zhang H, Zhang X, Zhou J, Chuanqing TU, Guan L, Yin Q, Shu R, Chen F, He M, Wang Q, Guo Z; Tumor and Microecology Committee of China Anti-Cancer Association; Chinese Collaborative Group on Transformation of Infectious Immunology and Microecology Research. Wang J, et al. Among authors: sun z. J Cancer Res Ther. 2023 Dec 1;19(6):1495-1500. doi: 10.4103/jcrt.JCRT_782_23. Epub 2023 Dec 28. J Cancer Res Ther. 2023. PMID: 38156914 Free article.
22,060 results
You have reached the last available page of results. Please see the User Guide for more information.